Overview

Baricitinib reaches its full potential in rheumatoid arthritis when added to methotrexate, so the combination question sits at the centre of how the drug is used in practice. Each PALUTINI pack provides 60 film-coated 4 mg tablets meant for a single daily oral dose. This article examines the synergy between JAK1/2 blockade and conventional synthetic DMARDs, and what procurement teams should stock for combination cohorts. Pairing the two classes is a standard step before moving to biologic therapy.

How It Works

Baricitinib is a selective Janus kinase 1 and 2 (JAK1/2) inhibitor that interrupts intracellular signalling triggered by cytokines such as interleukin-6 and interferon. In rheumatoid arthritis, overactive JAK pathways drive joint inflammation and damage. Methotrexate, a conventional DMARD, reduces immune activation through folate metabolism interference. Used together, the oral JAK inhibitor quenches cytokine signalling while methotrexate curbs upstream immune cell proliferation, producing a combined effect greater than either alone for many patients.

Indications

Baricitinib is indicated for moderate to severe active rheumatoid arthritis in adults who have responded inadequately to one or more disease-modifying antirheumatic drugs, commonly combined with methotrexate. The 60-tablet pack supports monthly once-daily therapy. It is also used in certain refractory skin and hair-loss indications per local labelling. Combination candidates are those failing methotrexate monotherapy or oral synthetic DMARDs.

Dosage & Administration

For RA, baricitinib is taken as one 4 mg tablet once daily, with or without methotrexate and food. A 60-tablet box covers one month. Dose adjustments apply for renal impairment or interacting medicines, and the labelled maximum should not be exceeded. Tablets are swallowed whole; therapy is continuous and reviewed against treatment targets such as remission or low disease activity.

Storage & Sourcing

Store below 30°C in the original blister, protected from moisture. Baricitinib is prescription-only; B2B supply needs licensed sourcing and market registration. Since it is frequently paired with methotrexate, buyers should coordinate both products so combination starters begin without delay. Confirm batch expiry and certificate of analysis on arrival, and track inventory against monitored outpatient cohorts.

FAQ

Q: Why add baricitinib to methotrexate rather than switch? A: JAK1/2 blockade and methotrexate act at different points in the inflammatory cascade, so combining often achieves disease control that neither achieves alone.

Q: Does the 4 mg dose change when combined with other drugs? A: Renal function and interacting medicines can lower the permitted dose; the labelled maximum must be respected and reviewed per patient.

Q: What should buyers coordinate for combination starters? A: Stock both baricitinib and methotrexate so newly combined patients receive a full regimen without a supply gap during the first month.